Bausch+Lomb Results Presentation Deck slide image

Bausch+Lomb Results Presentation Deck

YTD Total Bausch + Lomb P&L¹ (Non-GAAP)² Bausch + Lomb Vision Care Revenue4 Surgical Revenue Pharmaceuticals Revenue 4 Total Revenue Adj. Gross Profit² Adj. Gross Margin² Adj. R&D² Adj. R&D % of Revenues Adj. SG&A² Adj. SG&A % of Revenues³ Adj. EBITA² Depreciation Stock Based Compensation Adj. EBITDA 2,3 Adj. EBITDA Adj. Net Income Attributable to B+L² Adj. EPS Attributable to B+L2,4 BAUSCH+ LOMB 1Q23-3Q23 $1,881 M $563M $529M $2,973 M $1,794M 60.3% $243M 8.2% $1,185M 39.9% $366M $106M $58M $507M 17.1% $175M $0.50 1Q22-3Q225 $1,745M $530M $497M $2,772M $1,673M 60.4% $229M 8.3% $1,060M 38.2% $383M $98M $45M $539M 19.4% $295M $0.84 1. Products with sales outside the United States impacted by F/X changes. 2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios. Reported Change 8% 6% 6% 7% 7% (10 bps) (6%) (12%) (4%) 8% 29% (6%) (41%) Constant Currency Change² 11% 7% 8% 9% 10% (6%) (13%) 1% 7% 29% (2%) (34%) 3. Includes transactional FX and NCI. FX headwinds (translational and transactional) were -$52M to Adj. EBITDA for YTD2023. The YTD2022 transactional FX impact was a gain of $15M. 4. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure. 5. YTD 2022 results were not fully burdened by all stand-up costs associated with the separation. 27
View entire presentation